Why the study?
Does dabigatran prevent stroke and venous thromboembolism in patients with non-valvular atrial fibrillation, after orthopedic surgery, or with acute venous thromboembolism?
Does dabigatran prevent stroke and venous thromboembolism in patients with non-valvular atrial fibrillation, after orthopedic surgery, or with acute venous thromboembolism?
Dabigatran is an effective and safe alternative to standard anticoagulants for stroke and VTE prevention, offering a predictable pharmacokinetic profile without the need for routine monitoring.
May support dabigatran as alternative for AF/VTE; leaves open need for updated head-to-head trials.
Dabigatran, an oral direct thrombin inhibitor, was the first of a new class of drugs referred to as non-vitamin K oral anticoagulants. Dabigatran is better than warfarin for stroke prevention in non-valvular atrial fibrillation (dose of 150 mg twice a day), non-inferior to enoxaparin for venous thromboembolism prevention after orthopedic surgery and non-inferior to warfarin in preventing recurrence after acute venous thromboembolism. The safety profile is similar to standard anticoagulants, with significant reduction observed in intracranial hemorrhage. Other advantages include a rapid onset of action and a predictable pharmacokinetic profile, allowing a fixed-dose regimen without the need for routine anticoagulation monitoring. In the event of bleeding, general support measures are recommended and if severe, the use of non-specific hemostatic agents such as prothrombin complex concentrates and recombinant factor VIIa must be considered. A specific reversal agent (idarucizumab) is in development.
No takes yet. Share an insight, caveat, or question.
Enríquez et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: